O	0	11	Differences
O	12	14	in
O	15	21	breast
O	22	28	cancer
O	29	33	risk
O	34	41	factors
O	42	44	by
B-intervention	45	50	tumor
I-intervention	51	57	marker
I-intervention	58	66	subtypes
O	67	72	among
O	73	86	premenopausal
B-ethinicity	87	97	Vietnamese
O	98	101	and
B-ethinicity	102	109	Chinese
O	110	115	women
O	115	116	.

O	117	119	We
O	120	129	evaluated
O	130	142	associations
O	143	150	between
O	151	163	reproductive
O	164	167	and
O	168	177	lifestyle
O	178	182	risk
O	183	190	factors
O	191	195	with
O	196	202	breast
O	203	209	cancer
O	210	215	tumor
O	216	222	marker
O	223	229	status
O	230	232	in
O	233	234	a
O	235	239	case
O	239	240	-
O	240	247	control
O	248	253	study
O	253	254	.

O	255	260	Cases
O	261	265	were
B-eligibility	266	279	premenopausal
I-eligibility	280	285	women
O	286	292	living
O	293	295	in
B-location	296	303	Vietnam
O	304	307	and
B-location	308	313	China
O	314	317	who
O	318	322	were
O	323	331	eligible
O	332	335	for
O	336	337	a
O	338	346	clinical
O	347	352	trial
O	353	355	of
O	356	368	oophorectomy
O	369	372	and
O	373	382	tamoxifen
O	383	385	as
O	386	395	treatment
O	396	399	for
O	400	406	breast
O	407	413	cancer
O	414	415	(
O	415	416	n
O	417	418	=
B-intervention-participants	419	422	682
O	422	423	)
O	423	424	.

B-control	425	433	Controls
O	434	438	were
O	439	450	nonrelative
O	451	459	hospital
O	460	468	visitors
O	468	469	,
O	470	477	matched
O	478	480	on
O	481	484	age
O	485	487	to
O	488	491	the
O	492	497	cases
O	498	499	(
O	499	500	n
O	501	502	=
B-control-participants	503	506	649
O	506	507	)
O	507	508	.

O	509	528	Immunohistochemical
O	529	537	analysis
O	538	541	was
O	542	546	used
O	547	549	to
O	550	558	identify
O	559	562	the
O	563	571	presence
O	572	574	of
O	575	583	estrogen
O	584	592	receptor
O	593	594	(
O	594	596	ER
O	596	597	)
O	598	601	and
O	602	614	progesterone
O	615	623	receptor
O	624	627	and
O	628	631	the
O	632	646	overexpression
O	647	649	of
O	650	653	HER
O	653	654	-
O	654	655	2
O	655	656	/
O	656	659	neu
O	660	668	oncogene
O	668	669	.

O	670	674	Odds
O	675	681	ratios
O	682	683	(
O	683	685	OR
O	685	686	)
O	687	690	and
O	691	693	95
O	693	694	%
O	695	705	confidence
O	706	715	intervals
O	716	717	(
O	717	719	95
O	719	720	%
O	721	723	CI
O	723	724	)
O	725	729	were
O	730	739	estimated
O	740	745	using
O	746	759	unconditional
O	760	768	logistic
O	769	779	regression
O	779	780	,
O	781	789	adjusted
O	790	793	for
O	794	799	known
O	800	811	confounders
O	811	812	.

O	813	820	Overall
O	820	821	,
O	822	825	280
O	826	827	(
O	827	829	61
O	829	830	%
O	830	831	)
O	832	837	tumor
O	838	845	samples
O	846	850	were
O	851	853	ER
O	854	862	positive
O	863	866	and
O	867	870	176
O	871	872	(
O	872	874	38
O	874	875	%
O	875	876	)
O	877	881	were
O	882	884	ER
O	885	893	negative
O	893	894	.

O	895	898	HER
O	898	899	-
O	899	900	2
O	900	901	/
O	901	904	neu
O	905	919	overexpression
O	920	923	was
O	924	932	detected
O	933	935	in
O	936	939	161
O	940	941	(
O	941	943	35
O	943	944	%
O	944	945	)
O	946	953	samples
O	953	954	,
O	955	962	whereas
O	963	966	286
O	967	968	(
O	968	970	26
O	970	971	%
O	971	972	)
O	973	980	samples
O	981	985	were
O	986	989	HER
O	989	990	-
O	990	991	2
O	991	992	/
O	992	995	neu
O	996	1004	negative
O	1004	1005	.

O	1006	1008	We
O	1009	1017	observed
O	1018	1020	an
O	1021	1028	inverse
O	1029	1034	trend
O	1035	1042	between
O	1043	1053	increasing
O	1054	1060	parity
O	1061	1064	and
O	1065	1075	decreasing
B-outcome	1076	1082	breast
I-outcome	1083	1089	cancer
I-outcome	1090	1094	risk
O	1095	1096	(
O	1096	1097	P
O	1098	1099	=
O	1100	1101	0
O	1101	1102	.
O	1102	1105	002
O	1105	1106	)
O	1106	1107	.

O	1108	1113	Women
O	1114	1118	ages
O	1119	1120	>
O	1121	1123	or
O	1124	1125	=
O	1125	1127	25
O	1128	1133	years
O	1134	1136	at
O	1137	1142	first
O	1143	1148	birth
O	1149	1152	had
O	1153	1162	increased
B-outcome	1163	1169	breast
I-outcome	1170	1176	cancer
I-outcome	1177	1181	risk
O	1182	1190	compared
O	1191	1195	with
O	1196	1201	women
O	1202	1206	ages
O	1207	1208	<
O	1208	1210	25
O	1211	1216	years
O	1217	1219	at
O	1220	1225	first
O	1226	1231	birth
O	1232	1233	(
O	1233	1235	OR
O	1235	1236	,
O	1237	1238	1
O	1238	1239	.
O	1239	1241	53
O	1241	1242	;
O	1243	1245	95
O	1245	1246	%
O	1247	1249	CI
O	1249	1250	,
O	1251	1252	1
O	1252	1253	.
O	1253	1255	20
O	1255	1256	-
O	1256	1257	1
O	1257	1258	.
O	1258	1260	95
O	1260	1261	)
O	1261	1262	.

O	1263	1268	Women
O	1269	1272	who
O	1273	1281	consumed
O	1282	1289	alcohol
O	1290	1293	had
O	1294	1303	increased
B-outcome	1304	1308	risk
I-outcome	1309	1311	of
I-outcome	1312	1318	breast
I-outcome	1319	1325	cancer
O	1326	1334	compared
O	1335	1339	with
O	1340	1345	women
O	1346	1349	who
O	1350	1353	did
O	1354	1357	not
O	1358	1359	(
O	1359	1361	OR
O	1361	1362	,
O	1362	1363	1
O	1363	1364	.
O	1364	1366	85
O	1366	1367	;
O	1368	1370	95
O	1370	1371	%
O	1372	1374	CI
O	1374	1375	,
O	1376	1377	1
O	1377	1378	.
O	1378	1380	32
O	1380	1381	-
O	1381	1382	2
O	1382	1383	.
O	1383	1385	61
O	1385	1386	)
O	1386	1387	.

O	1388	1396	Compared
O	1397	1401	with
O	1402	1410	controls
O	1410	1411	,
B-outcome	1412	1414	OR
O	1415	1424	estimates
O	1425	1428	for
O	1429	1435	breast
O	1436	1442	cancer
O	1443	1445	by
O	1446	1452	parity
O	1453	1456	and
O	1457	1460	age
O	1461	1463	at
O	1464	1469	first
O	1470	1475	birth
O	1476	1480	were
O	1481	1494	significantly
O	1495	1505	associated
O	1506	1510	with
O	1511	1513	ER
O	1514	1517	and
O	1517	1518	/
O	1518	1520	or
O	1521	1524	HER
O	1524	1525	-
O	1525	1526	2
O	1526	1527	/
O	1527	1530	neu
O	1531	1536	tumor
O	1537	1543	status
O	1544	1546	by
O	1547	1551	Wald
O	1552	1556	test
O	1557	1558	(
O	1558	1559	P
O	1560	1561	<
O	1562	1563	0
O	1563	1564	.
O	1564	1566	05
O	1566	1567	)
O	1567	1568	.

O	1569	1575	Family
O	1576	1583	history
O	1583	1584	,
O	1585	1588	age
O	1589	1591	at
O	1592	1600	menarche
O	1600	1601	,
O	1602	1612	cumulative
O	1613	1622	lactation
O	1622	1623	,
O	1624	1628	body
O	1629	1633	mass
O	1634	1639	index
O	1639	1640	,
O	1641	1644	and
O	1645	1654	education
O	1655	1659	were
O	1660	1663	not
O	1664	1677	significantly
O	1678	1685	related
O	1686	1688	to
O	1689	1695	breast
O	1696	1702	cancer
O	1703	1707	risk
O	1707	1708	.

O	1709	1712	Our
O	1713	1721	findings
O	1722	1729	support
O	1730	1733	the
O	1734	1744	hypothesis
O	1745	1749	that
O	1750	1754	some
O	1755	1761	breast
O	1762	1768	cancer
O	1769	1773	risk
O	1774	1781	factors
O	1782	1788	differ
O	1789	1791	by
O	1792	1794	ER
O	1795	1798	and
O	1799	1802	HER
O	1802	1803	-
O	1803	1804	2
O	1804	1805	/
O	1805	1808	neu
O	1809	1814	tumor
O	1815	1821	marker
O	1822	1830	subtypes
O	1830	1831	.
